A recent study reveals that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who halt traditional diet and exercise programs.
Published data in a prominent medical journal shows that while obese individuals often shed about a fifth of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs should be aware of the potential of quick weight regain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment weight in about 18 months.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
The team point out that people who lose weight through diet and exercise generally experience a less rapid weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Experts suggest the way of the injections is key to understanding the heightened regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone levels far above than the body's typical production may cause the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Health authorities suggest the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy might need to be ongoing.
This perspective is supported by drug manufacturers, who state that the results "emphasize the long-term nature of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
Individuals who have discontinued the jabs describe a powerful resurgence of cravings.
"It was like a switch flipping and you're instantly ravenous," recalled a patient.
The struggle is worsened if patients have not established lasting lifestyle or habit changes during treatment.
Widespread Interest
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among women than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while the jabs are powerful agents for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle changes.
